

# The PPRI Indicators online tool – a reporting system for indicators to describe, measure and analyse pricing and reimbursement policies & systems

Alexander Haasis

PPRI Secretariat  
WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies  
Pharmacoeconomics Department  
Gesundheit Österreich (GÖG / Austrian National Public Health Institute)

PPRI Network Meeting

Vienna, 24 April 2024



Gesundheit Österreich  
GmbH ● ● ●

# Declaration of interest and disclaimer

The PPRI Secretariat is hosted by the Pharmacoeconomics Department at GÖG. GÖG is owned by the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection.

Coordination activities of PPRI Secretariat are funded by the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection.


## Disclaimer:

The information and data provided in this presentation was collected and analysed by the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies located at the Pharmacoeconomics Department of GÖG.

The data do not have any legally binding value. This is not a presentation of WHO. The presenter is responsible for the views expressed in this presentation, and they do not necessarily represent the decisions and policies of the WHO.

# The PPRI Indicators

- Based on collection of **key data on pharmaceutical systems and policy measures** in PPRI member countries
- PPRI Indicators provide information to **describe, measure and evaluate** the **design and performance** of pharmaceutical systems and policies with a focus on pricing and reimbursement
- **No duplication** of indicators already covered by other databases
- **Pilot of PPRI Indicators online database (dashboard) launched in April 2024!**



# PPRI Indicators – main categories

1. Price regulation
2. External price referencing
3. Internal price referencing
4. Value-based pricing
5. Tendering
6. Cost-plus pricing
7. Distribution remuneration
8. Taxes
9. Reimbursement lists
12. Reimbursement rates
13. Co-payments
14. Reference Price System
15. INN prescribing
16. Generic / biosimilar substitution
17. Horizon Scanning & HTA
18. Managed-entry agreements
- ...

# Examples of PPRI indicators

## Price regulation

- Indicator: Scope of price control for medicines
- Indicator: Price types regulated

## Indicator „Scope of price control for medicines“

- All medicines
- Reimbursable medicines
- Prescription-only medicines
- Other groups of medicines
- No medicines under price regulation
- No information available

## External Price Referencing

- Indicator: Use of EPR
- Indicator: Methodology to determine the reference price under EPR
- Indicator: Number of reference countries
- Indicator: Scope of EPR (sectors covered)

## Indicator „Methodology to determine the reference price“

- Average / median price of reference countries
- Lowest price of reference countries
- Other calculation method
- No method defined
- No external price referencing
- No medicines under price regulation
- No information available

## Reimbursement rates

- Indicator: Reimbursement rates of medicines in the outpatient sector
- Indicator: Reimbursement rates of medicines in the inpatient sector

## Co-payments

- Indicator: Co-payments for funded medicines in outpatient sector
- Indicator: Types of co-payments for funded medicines in outpatient sector

## Reference Price System

- Indicator: Reference price system in place
- Indicator: Cluster of reference groups
- Indicator: Calculation of reference prices

# The PPRI Indicators online tool (dashboard)

- Allows **easy (and open) access** to key data on pharmaceutical systems and policies in the PPRI member countries
- Outputs are visualized through **country maps, graphs, and tables** and can be exported in pdf.
- **Updated** continuously
- Further development:
  - Additional indicators are currently being developed
  - Possibility to download **country fact sheets** including all indicators

Indicator

3.1 Generic price link (for validation) ▾


2023 ▾

Countries

All countries ▾

Export

The indicator describes which PPRI countries regulate the prices of generic medicines by setting the price of a generic at a defined amount (e.g., percentage) lower than the price of the originator medicine.



● Generic price link

● No generic price link

● No medicines under price regulation

● No information available

● Not a PPRI member country

Generic price link: Australia, Brazil, Canada, Egypt, Israel, Kazakhstan, Republic of Korea, Saudi Arabia, South Africa  
 No medicines under price regulation: Armenia, Kyrgyzstan, Singapore

Category	# of countries (n=50)	Name of country
Generic price link	37	Albania, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Croatia, Czech Republic, Egypt, Estonia, Finland, France, Greece, Hungary, Ireland, Israel, Italy, Kazakhstan, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Republic of Cyprus, Republic of Korea, Republic of Moldova, Republic of Serbia, Romania, Saudi Arabia, Slovakia, South Africa, Spain, Sweden, Switzerland, Türkiye
No generic price link	10	Denmark, Germany, Iceland, Kosovo, Malta, Netherlands, North Macedonia, Slovenia, Ukraine, United Kingdom of Great Britain and Northern Ireland
No medicines under price regulation	3	Armenia, Kyrgyzstan, Singapore
No information available	0	

Indicator Last Updated:

Definition

Results map

Summary table

# Example: Reference Price System

## PPRI Indicators - 2023

### 12.1 Reference price system (for validation)




Indicator: 12.1 Reference price system (for validation) | 2023

Countries: All countries

Export

The indicator informs about which PPRI countries have implemented a reference price system (RPS). A RPS is a reimbursement policy in which medicines that are considered interchangeable (e.g., identical medicines (ATC level 5) or similar medicines (e.g., ATC level 4)) are clustered into so-called reference groups. The public payer funds a defined maximum amount (the reference price), which is the same for all medicines in one reference group. If a medicine's pharmacy retail price exceeds its reference price, the patient usually has to pay the difference, in addition to any other co-payments, if applicable.



Reference price system in place: Australia, Egypt, Israel, Kyrgyzstan, Saudi Arabia, Singapore  
 No reference price system in place: Armenia, Brazil, Canada, Kazakhstan, Republic of Korea, South Africa

[Information shown is not correct?](#)

Category	# of countries (n=50)	Name of country
Reference price system in place	36	Albania, Australia, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Kyrgyzstan, Latvia, Lithuania, Netherlands, North Macedonia, Norway, Poland, Portugal, Republic of Cyprus, Republic of Serbia, Romania, Saudi Arabia, Singapore, Slovakia, Slovenia, Spain, Türkiye, Ukraine
No reference price system in place	14	Armenia, Austria, Brazil, Canada, Kazakhstan, Kosovo, Luxembourg, Malta, Republic of Korea, Republic of Moldova, South Africa, Sweden, Switzerland, United Kingdom of Great Britain and Northern Ireland
No information available	0	

## PPRI Indicators - 2023

### 12.2 Reference price system - Cluster of reference groups (for validation)




Indicator: 12.2 Reference price system - Cluster of reference groups... | 2023

Countries: All countries

Export

The indicator informs how the reference groups within a reference price system (RPS) are clustered in the PPRI countries. This is a reimbursement policy in which medicines that are considered interchangeable (e.g., identical medicines (Anatomic Therapeutic Chemical (ATC) 5) or similar medicines (e.g., ATC 4)) are clustered into so-called reference groups. The public payer funds a defined maximum amount (the reference price), which is the same for all medicines in one reference group. If a medicine's pharmacy retail price exceeds its reference price, the patient usually has to pay the difference, in addition to any other co-payments, if applicable.



Reference price system in place, ATC 5 cluster: Israel, Kyrgyzstan, Saudi Arabia  
 Reference price system in place, broader clusters than ATC 5: Egypt  
 No reference price system in place: Armenia, Brazil, Canada, Kazakhstan, Republic of Korea, South Africa  
 No information available: Australia, Singapore

[Information shown is not correct?](#)

Category	# of countries (n=50)	Name of country
Reference price system in place, ATC 5 cluster	17	Albania, Belgium, Denmark, Finland, France, Iceland, Ireland, Israel, Italy, Kyrgyzstan, Norway, Portugal, Saudi Arabia, Slovakia, Spain, Türkiye, Ukraine
Reference price system in place, broader clusters than ATC 5	16	Bulgaria, Croatia, Czech Republic, Egypt, Estonia, Germany, Greece, Hungary, Latvia, Lithuania, Netherlands, North Macedonia, Poland, Republic of Cyprus, Romania, Slovenia
No reference price system in place	14	Armenia, Austria, Brazil, Canada, Kazakhstan, Kosovo, Luxembourg, Malta, Republic of Korea, Republic of Moldova, South Africa, Sweden, Switzerland, United Kingdom of Great Britain and Northern Ireland

# PPRI Indicator validation April 2024

- Kindly check whether the data for your country is correctly shown in the PPRI Indicators dashboard for the year 2023 by using the validation sheet sent by the PPRI Secretariat and inform about changes in the year 2024
- After validation period (deadline 10 May 2024), the PPRI Secretariat will upload any submitted changes to the dashboard.

Thank you very much for your support!

**PPRI**  
Pharmaceutical Pricing and Reimbursement Information

**PPRI Indicators: Meta Information on pharmaceutical pricing and reimbursement information**  
**Validation sheet**  
**Austria**

Thank you for having provided data and information on your country throughout the years.

Based on the data you provided, we have developed a sustainable reporting and visualisation system for meta-indicators – the **PPRI Indicators Dashboard** – to describe, measure and analyse pricing and reimbursement systems and policies in PPRI member countries.

We would kindly ask you to validate the data in the PPRI Indicators Dashboard test version. The dashboard (test version) can be accessed via this link: <https://ppriindicators.qoeg.at/>. Please note that this is still an **internal version**, so kindly neither disseminate nor use any of the included information as it is yet to be validated.

To enable the validation, we prepared this validation sheet. We would like to ask you to **click through the different indicators in the dashboard (via the drop-down menu)** and validate whether the information provided is still correct. Kindly note that the included indicators relate to the **year 2023**, so please validate the correctness of the indicators for the year 2023 and indicate any changes for 2024. Kindly note any relevant information (e.g., incorrect data, changes during the year, additional data for missing information) in the table on the next page. We also appreciate additional information not captured in the maps in the Dashboard.

For further information:

- » **Definitions** of the terms can be found in the glossary: <https://ppri.qoeg.at/ppri-glossary/>.
- » To put the information in the **context of other PPRI countries**, kindly consult the [PPRI Report 2018](#).

In case of queries, do not hesitate to consult [ppri@qoeg.at](mailto:ppri@qoeg.at).

Kindly return the validated table by **10 May 2024**. **Please remember to validate for the year 2023.**

Thank you for your cooperation!

The PPRI Secretariat

The validation was done by:  
 Name: Valentin Kandler  
 Institution: Austrian National Public Health Institute / Gesundheit Österreich GmbH  
 Country: Austria  
 Date: 18 April 2024

Indicator	Correct data for 2023 (please write Y/N or Yes/No)	If not correct for the year 2023 – please explain and provide correct information	If any changes for the year 2024 have already been implemented or are planned, please inform us about the change. What was changed or will change? And when? (pls. indicate the month of 2024)
<b>Price Regulation</b>			
1.1 Scope of price control for medicines (for validation)	Y		Correct as of 2024
1.2 Price types regulated (for validation)	Y		Correct as of 2024
<b>External Price Referencing</b>			
2.1 Use of External Price Referencing (for validation)	Y		Correct as of 2024
2.2 Methodology to determine the reference price under external price referencing (for validation)	Y		Correct as of 2024
2.3 Number of reference countries to determine the reference price under external price referencing (for validation)	Y		Correct as of 2024
2.4 Scope of EPR: sectors covered (for validation)	Y		Correct as of 2024
<b>Internal Price Referencing</b>			
3.1 Generic price link (for validation)	Y		Correct as of 2024
3.1.1 Generic price link: Extent of price reductions for generics (for validation)	Y		Correct as of 2024
3.1.2 Generic price link: Medicines targeted (for validation)	Y		Correct as of 2024
3.2 Biosimilar price link (for validation)	Y		Correct as of 2024
3.2.1 Biosimilar price link: Extent of price reductions for biosimilars (for validation)	Y		Correct as of 2024
3.2.2 Biosimilar price link: Medicines targeted (for validation)	Y		Correct as of 2024
3.3 Generic and biosimilar price link (for validation)	Y		Correct as of 2024
<b>Value-based pricing</b>			
4.1 Value-based pricing for new medicines (for validation)	Y		Correct as of 2024
<b>Other pricing</b>			
5.1 Tendering in place (for validation)	Y		Correct as of 2024
5.2 Tendering in the outpatient sector (for validation)	Y		Correct as of 2024
5.3 Tendering in the inpatient sector (for validation)	Y		Correct as of 2024
5.4 Price-based pricing (for validation)	Y		Correct as of 2024
<b>Remuneration</b>			
6.1 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.2 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.3 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.4 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.5 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.6 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.7 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.8 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.9 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.10 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.11 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.12 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.13 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.14 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.15 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.16 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.17 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.18 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.19 Wholesale remuneration (for validation)	Y		Correct as of 2024
6.20 Wholesale remuneration (for validation)	Y		Correct as of 2024



# PPRI Indicators Dashboard (web-tool) – time to try!

Accessible via following link:

<https://ppriindicators.goeg.at/>

Login required  
for test version!

**Indicators**

## What are PPRI indicators?

Comparative and up-to-date country information is of key importance for policy-makers, technical experts and researchers in the field. However, information on pharmaceutical systems, particularly information related to pharmaceutical pricing and reimbursement systems, is often not publicly available or difficult to access.

To respond to this need, the PPRI Secretariat at the Austrian National Public Health Institute developed the PPRI indicators dashboard, which allows easy access to key data on pharmaceutical systems in the PPRI member countries (currently 50 countries, including all 27 EU Member States).

The dashboard provides a wide variety of indicators on pharmaceutical systems characteristics and policies with outputs being visualized through country maps, graphs, and tables. Indicators can be used to describe, measure and evaluate the design and performance of national pharmaceutical systems and policies in the own country and in comparison with other countries. Results may also lay the basis for further comparative pharmaceutical systems research.

As of 2023, the PPRI indicators dashboard includes more than 20 categories on key pharmaceutical systems characteristics and policies comprising over 65 indicators. Indicator outputs provide answers to key questions in pharmaceutical policy research, such as:

- Which PPRI countries regulate medicine prices and for which medicines?
- Which countries apply external and or internal price referencing and what are the specific modalities?
- Is value-added tax imposed to medicines, and, if yes, do the rates differ from standard VAT rates?
- What types of co-payments are in place?
- Which countries use managed entry agreements?

The PPRI Secretariat aims to focus on indicators for which information has not already been published by other institutions or databases. Data are regularly collected and updated.

### Methodology

The PPRI Secretariat developed qualitative and quantitative indicators based on available taxonomies of indicators for the description and evaluation of pharmaceutical systems ([PHIS indicators Taxonomy, 2009](#)). The data for these indicators have been collected by the PPRI Secretariat through partially pre-filled surveys which were answered by the PPRI network members. The staff of the PPRI Secretariat conducts a final review before entering the validated data into a database and uploading them to the PPRI indicators dashboard.

### How to quote:

PPRI Indicators 2023. Austrian National Public Health Institute. Accessible online: <https://ppriindicators.goeg.at/>


We look  
forward to  
your  
feedback!

Username and password for today:

Username: **ppri**

Password: **PPRI2024a**

# Thank you for your attention



The screenshot shows the PPRI website homepage. At the top left is the PPRI logo (Pharmaceutical Pricing and Reimbursement Information) and a search bar labeled 'Keywords'. Below the logo is a navigation menu with items: ABOUT, EXPERTISE, SERVICES, PUBLICATIONS, GLOSSARY, EVENTS, DE, ES, RU, MEMBERS. The main banner features a hand holding a pen over a complex gear mechanism, with the text 'PPRI networks' and navigation arrows. Below the banner is a mission statement: 'We aim to contribute to affordable, equitable and sustainable access to safe, effective and quality essential medicines in Austria, Europe and globally.' The main content area is divided into three columns. The left column has a title 'How to mitigate medicine shortages? Learnings from 38 countries' and a 'More' button. The middle column has a title 'Austrian partners contributing to making EU healthcare sector procurement practices more effective and resilient' and a 'More' button. The right column has a title '5th PPRI Conference 2024 - Register now!' and a 'More' button. To the right of these columns are sections for 'NEWS' (listing three newsletters) and 'QUICKLINKS' (listing PPRI, WHO.CC, PPI, and GÖG). At the bottom is a dark navigation bar with links for CONTACT, INFORMATION, LINKS, and NEWSLETTER.

**Alexander Haasis**

PPRI Secretariat

Pharmacoeconomics Department

WHO Collaborating Centre for

Pharmaceutical Pricing and Reimbursement Policies

**Gesundheit Österreich GmbH (GÖG /  
Austrian National Public Health Institute)**

Stubenring 6

1010 Vienna

T: +43 1 515 61 269

[alexander.haasis@goeg.at](mailto:alexander.haasis@goeg.at)

[ppri.goeg.at](http://ppri.goeg.at) & [www.goeg.at](http://www.goeg.at)